Description
Celsentri (maraviroc) is a critical antiretroviral medication used to treat HIV infection in patients 2 years and older. It functions as a CCR5 antagonist, specifically blocking the CCR5 co-receptor on the surface of CD4 cells. This action prevents the HIV virus from entering these immune cells, thereby hindering its ability to replicate and spread within the body. As part of a comprehensive treatment regimen, Celsentri not only lowers the viral load but also helps preserve immune function, contributing to better overall health in individuals living with HIV.
In clinical practice, Celsentri is often utilized alongside other antiretroviral agents to optimize therapeutic outcomes. The selection of Celsentri is guided by the HIV strain’s co-receptor tropism, ensuring that it targets the virus effectively. Patients receiving Celsentri can experience improved quality of life and enhanced immune response, making it a valuable option in modern HIV management.